Momenta Pharmaceuticals (MNTA) 18.62 $MNTA Nasdaq stocks

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 9:55 PM

Momenta Pharmaceuticals (MNTA) 18.62 $MNTA

Nasdaq stocks posting largest percentage increases
AP - Tue Apr 21, 12:45PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
TTS: 14.52 (-0.33), HAS: 71.73 (-1.82), AMSC: 10.40 (+1.20), ECHO: 33.39 (+1.37), LJPC: 23.04 (+1.22), RMBS: 14.40 (+0.22), TGLS: 11.98 (+0.70), VLTC: 15.14 (-1.04), MNTA: 18.62 (+0.56), SPKE: 12.97 (+0.09), ROVI: 19.46 (+0.10)

Momenta Pharmaceuticals Has Returned 49.2% Since SmarTrend Recommendation (MNTA)
Comtex SmarTrend(R) - Tue Apr 21, 11:24AM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on February 18th, 2015 at $12.52. In approximately 2 months, Momenta Pharmaceuticals has returned 49.18% as of today's recent price of $18.67.
MNTA: 18.62 (+0.56)

Teva Bids $40 Billion For Mylan, But May Need More
at Investor's Business Daily - Tue Apr 21, 10:35AM CDT
Israeli drug giant Teva Pharmaceutical Industries (TEVA) made its long-awaited bid for competitor Mylan on Tuesday, offering $82 a share, or $40.1 billion. Both stocks rose on the news. Teva's proposal, half cash and half stock, was unsolicited by...
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)

A Look at the Health of the HealthCare Sector: Complementary Research on Horizon Pharma, Enzon Pharmaceuticals, Momenta Pharmaceuticals, Athersys, and Pernix Therapeutics
PR Newswire - Tue Apr 21, 9:46AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENZN: 1.70 (+0.20), PTX: 7.44 (-0.05), HZNP: 30.96 (+0.10), ATHX: 1.34 (+0.01), MNTA: 18.62 (+0.56)

Looking For Action? S&P 1500 Most Volatile Stocks
Bespoke Investment Group - at Seeking Alpha - Tue Apr 21, 3:30AM CDT
For traders with a short-term time horizon who are looking for big moves over a short period, we have updated our list of the 50 S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread...
CRR: 33.68 (-0.12), NBR: 15.05 (+0.68), BCEI: 24.50 (-0.20), LL: 33.86 (+0.50), PTEN: 21.01 (+0.68), MNTA: 18.62 (+0.56), HOS: 20.11 (-0.89), KOP: 22.68 (+0.05), DO: 30.07 (-0.02), BBG: 9.80 (-0.41), SGY: 16.54 (-0.83), FTK: 15.56 (+0.10), SPN: 23.84 (+0.41), ROVI: 19.46 (+0.10), WPX: 13.40 (+0.16), AKRX: 53.70 (-1.69), MCF: 20.44 (-0.02), ZEUS: 10.79 (-0.32), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), CCRN: 11.10 (+0.01), ESV: 24.03 (+0.13), ANIP: 69.79 (+1.24), SGNT: 25.43 (-0.29), PDCE: 55.02 (-0.03), NE: 16.18 (+0.14), UIHC: 20.78 (+0.18), TNGO: 14.04 (-0.16), SGMS: 12.48 (+0.25), GIFI: 15.33 (+0.25), TDW: 24.66 (-0.59), CENX: 13.28 (+0.17), UNT: 30.38 (+0.43), RIG: 16.85 (-0.18), SPOK: 20.73 (+0.23), GPRE: 30.59 (-0.02), SYRG: 12.37 (+0.06), GEOS: 20.76 (+0.57), CBM: 42.07 (-0.65), SM: 55.21 (+1.23), TESO: 12.48 (+0.09), ROSE: 22.02 (-0.50), RGEN: 33.37 (+0.51), VDSI: 25.11 (-0.58), SKYW: 14.22 (unch), GLF: 13.77 (-0.11), SLCA: 36.94 (+0.70), RDC: 19.42 (-0.13), EHTH: 11.44 (+0.07)

Momenta Presents Key Glatopa(TM) (glatiramer acetate injection) Data at American Academy of Neurology Annual Meeting
GlobeNewswire - Mon Apr 20, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today presented new data from studies conducted as part of the ANDA submission for once daily Glatopa (glatiramer acetate injection) at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C. The posters presented provide examples of a selection of methods the Company utilized to show the equivalence of Glatopa and once daily COPAXONE 20 mg.
MNTA: 18.62 (+0.56)

Novartis and Momenta Get FDA Nod For Generic Copaxone - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:10PM CDT
Novartis AG (NVS) announced that its generic arm has received FDA approval for Glatopa, the first generic version of Teva Pharmaceuticals' (TEVA) multiple sclerosis drug, Copaxone.
MNK: 122.95 (-2.22), TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)

FDA approves generic version of top-selling MS drug Copaxone
AP - Fri Apr 17, 12:17PM CDT
NEW YORK (AP) — Two drugmakers are preparing to sell a lower-cost version of Copaxone, the world's most-widely used drug for multiple sclerosis.
TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)

Strong On High Relative Volume: Momenta Pharmaceuticals (MNTA)
at The Street - Fri Apr 17, 9:10AM CDT
Trade-Ideas LLC identified Momenta Pharmaceuticals (MNTA) as a strong on high relative volume candidate
MNTA: 18.62 (+0.56)

Momenta Pharmaceuticals Inc. (MNTA) in Focus: Stock Jumps 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 8:21AM CDT
Momenta Pharmaceuticals Inc. (MNTA) was a big mover last session, as the company saw its shares rise over 6% on the day.
MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)

Momenta Pharmaceuticals Announces Data Presentations on Glatopa(TM) (glatiramer acetate injection) at the American Academy of Neurology's (AAN) 2015 Annual Meeting
GlobeNewswire - Fri Apr 17, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of two posters comparing gene expression profiles and additional methods used to show equivalence between Glatopa and daily COPAXONE 20 mg (glatiramer acetate injection). The posters will be presented at the 67 AAN Annual Meeting taking place April 18 - 25, 2015 in Washington, D.C.
MNTA: 18.62 (+0.56)

Momenta, Novartis get FDA OK
at Investor's Business Daily - Thu Apr 16, 5:43PM CDT
Sandoz, the generic division of Novartis (NVS), and its biotech partner Momenta Pharmaceuticals (MNTA) won approval from the FDA for the first generic version of Copaxone, a widely used multiple-sclerosis drug. The FDA denied a request by Copaxone's...
TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)

Look for Shares of Momenta Pharmaceuticals to Potentially Pullback after Yesterday's 6.09% Rise
Comtex SmarTrend(R) - Thu Apr 16, 4:16PM CDT
Momenta Pharmaceuticals (NASDAQ:MNTA) traded in a range yesterday that spanned from a low of $16.03 to a high of $20.43. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $16.53 on volume of 8.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MNTA: 18.62 (+0.56)

Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 16, 4:15PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Momenta Pharmaceuticals shares jumped...
TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)

Momenta, Novartis Win FDA Nod For Generic Copaxone
at Investor's Business Daily - Thu Apr 16, 1:39PM CDT
Sandoz, the generics division of Novartis (NVS), and its biotech partner Momenta Pharmaceuticals won FDA approval on Thursday for the first generic version of popular multiple-sclerosis drug Copaxone. The FDA denied a citizens' petition by Copaxone's...
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)

FDA clears generic version of Teva's Copaxone
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 12:07PM CDT

TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)

Momenta Pharmaceuticals Announces Conference Call Details Regarding FDA Approval for Glatopa(TM) (glatiramer acetate injection)
GlobeNewswire - Thu Apr 16, 11:54AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will conduct a conference call to discuss the approval of Glatopa(TM) (glatiramer acetate injection, formerly M356) 20mg/mL, the first substitutable generic for COPAXONE.
MNTA: 18.62 (+0.56)

Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
GlobeNewswire - Thu Apr 16, 11:31AM CDT
-- First generic multiple sclerosis product approved in the United States
MNTA: 18.62 (+0.56)

GPhA Launches Biosimilars Council, New Industry Group Will Educate and Advocate for Patient Access to Safe, Affordable Lifesaving Medicines
PR Newswire - Thu Apr 16, 11:17AM CDT
The Generic Pharmaceutical Association (GPhA) is pleased to announce today's launch of the Biosimilars Council, a division of GPhA.
MNTA: 18.62 (+0.56)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

IEHP's Wellness Center Launch Faces Delay in California

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Windward Bio Surges 68% in Nasdaq Debut

By Ryan Hughes Updated Nov 13, 2026 Category News Views 243

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

LaserAway Expands to 244 Clinics Over 20 Years

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...